Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 28106W103 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Commodore Capital LP
13G
|
9.9% |
6/2/2026
Event 5/26/2026
|
||
| Commodore Capital LP | 9.9% | |||
| Commodore Capital Master LP | 9.9% | |||
| Robert Egen Atkinson | 9.9% | |||
| Michael Kramarz | 9.9% | |||
|
TCG Crossover GP III, LLC
13G
|
9.9% |
6/3/2026
Event 5/27/2026
|
||
| TCG Crossover GP III, LLC | 9.9% | |||
| TCG Crossover Fund III, L.P. | 9.9% | |||
| Chen Yu | 9.9% | |||
|
ADAR1 Capital Management, LLC
13G
|
5.8% |
8/14/2026
Event 6/30/2026
|
||
| ADAR1 Capital Management, LLC | 5.8% | |||
| Daniel Schneeberger | 5.8% | |||
|
RA Capital Management, L.P.
13G
|
5.8% |
6/3/2026
Event 5/27/2026
|
||
| RA Capital Management, L.P. | 5.8% | |||
| Peter Kolchinsky | 5.8% | |||
| Rajeev Shah | 5.8% | |||
| RA Capital Healthcare Fund, L.P. | 5.8% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (3) | ||||
| BlackRock, Inc. 13G/A | 4.97% |
7/29/2026
Event 6/30/2026
|
||
|
Deep Track Capital, LP
13G/A
|
0% |
2/14/2025
Event 12/31/2024
|
||
| Deep Track Capital, LP | 0% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 0% | |||
| David Kroin | 0% | |||
| Vanguard Group Inc 13G/A | 0% |
3/26/2026
Event 3/13/2026
|
||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 7 | 53.8 k | $138 k |
| 2026 Q2 | 228 | 120 M | $391 M |
| 2026 Q1 | 216 | 51.8 M | $128 M |
| 2025 Q4 | 211 | 50.1 M | $103 M |
| 2025 Q3 | 207 | 43.9 M | $152 M |
| 2025 Q2 | 202 | 41.7 M | $91.8 M |
| 2025 Q1 | 204 | 44.0 M | $51.1 M |
| 2024 Q4 | 218 | 51.1 M | $64.8 M |
| 2024 Q3 | 243 | 55.9 M | $224 M |
| 2024 Q2 | 251 | 58.1 M | $271 M |
| 2024 Q1 | 244 | 72.6 M | $538 M |
| 2023 Q4 | 242 | 61.7 M | $625 M |
| 2023 Q3 | 238 | 61.7 M | $481 M |
| 2023 Q2 | 258 | 62.8 M | $517 M |
| 2023 Q1 | 250 | 53.0 M | $384 M |
| 2022 Q4 | 275 | 63.3 M | $563 M |
| 2022 Q3 | 292 | 48.3 M | $595 M |
| 2022 Q2 | 285 | 47.6 M | $566 M |
| 2022 Q1 | 286 | 45.6 M | $871 M |
| 2021 Q4 | 338 | 51.4 M | $1.37 B |
| 2021 Q3 | 371 | 52.4 M | $2.18 B |
| 2021 Q2 | 354 | 52.3 M | $2.98 B |
| 2021 Q1 | 343 | 53.2 M | $2.25 B |
| 2020 Q4 | 352 | 53.2 M | $3.76 B |
| 2020 Q3 | 261 | 55.2 M | $1.57 B |
| 2020 Q2 | 260 | 54.4 M | $1.63 B |
| 2020 Q1 | 221 | 51.0 M | $1.12 B |
| 2019 Q4 | 255 | 46.5 M | $1.38 B |
| 2019 Q3 | 205 | 45.4 M | $1.04 B |
| 2019 Q2 | 217 | 40.3 M | $997 M |
| 2019 Q1 | 233 | 37.5 M | $917 M |
| 2018 Q4 | 210 | 35.0 M | $796 M |
| 2018 Q3 | 219 | 34.6 M | $1.10 B |
| 2018 Q2 | 233 | 32.6 M | $1.17 B |
| 2018 Q1 | 215 | 31.6 M | $1.05 B |
| 2017 Q4 | 159 | 30.4 M | $934 M |
| 2017 Q3 | 128 | 29.1 M | $698 M |
| 2017 Q2 | 120 | 29.2 M | $490 M |
| 2017 Q1 | 107 | 27.8 M | $621 M |
| 2016 Q4 | 87 | 23.7 M | $385 M |
| 2016 Q3 | 75 | 22.2 M | $299 M |
| 2016 Q2 | 68 | 22.6 M | $550 M |
| 2016 Q1 | 50 | 18.2 M | $625 M |